Corteva vs Scotts Miracle-Gro
Add, change or remove companies; up to four.
KIRA’s take AI analyst
I put Corteva and Scotts Miracle-Gro side by side, using each one’s latest annual report. Here is what stands out:
- Corteva is the larger business, with $17.4B of revenue in fiscal 2025 against $3.4B for Scotts Miracle-Gro, about 5.1 times as much.
- Corteva grew revenue faster (2.9%, against −3.9%).
- Corteva turned more of its sales into free cash flow (16.2% FCF margin, against 8.0%).
- Scotts Miracle-Gro earned a higher return on the capital invested in it (13.4%, against 5.8%).
- Investors pay more for each dollar of Scotts Miracle-Gro’s earnings: a P/E of 49.9x against 7.9x for Corteva.
Who comes out ahead
Of the 9 measures where higher (or lower) is clearly better, how many each company leads.
Corteva
CTVA
8/9
Revenue growth5-year growthGross marginNet marginFCF marginPiotroski F-scoreNet debt / EBITDAShare count change
Scotts Miracle-Gro
SMG
1/9
Return on capital
Side by side
Best in the row
| Latest fiscal year | CTVA FY25 | SMG FY25 |
|---|---|---|
| Size | ||
| Market cap | $8.0B | $3.5B |
| Revenue | $17.4B | $3.4B |
| Free cash flow | $2.8B | $274M |
| Net income | $1.1B | $145M |
| Growth | ||
| Revenue growth | 2.9% | −3.9% |
| 5-year growth | 4.1% | −3.8% |
| Share count change | −2.1% | 3.4% |
| Profitability | ||
| Gross margin | 47.3% | 30.6% |
| Operating margin | — | 10.5% |
| Net margin | 6.3% | 4.3% |
| FCF margin | 16.2% | 8.0% |
| Return on capital | 5.8% | 13.4% |
| Return on equity | 4.6% | — |
| Balance sheet | ||
| Net debt | −$2.0B | $2.1B |
| Net debt / EBITDA | −0.6x | 4.8x |
| Dividends and buybacks | $1.5B | $173M |
| Valuation & quality | ||
| P/E | 7.9x | 49.9x |
| Piotroski F-score | 8 | 6 |
Ten years
Revenue
Operating margin
Free cash flow
Return on capital
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.